EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Yin Yang 1 Promotes Antiprogrammed Cell Death‐1 Resistance in Hepatocellular Carcinoma through Polypeptide N‐Acetylgalactosaminyltransferase 16‐Mediated Glycosylation of Programmed Death Ligand‐1

Shu-Sheng Lin, Gang Xiao iD, Qin-Qin Liu, Jia-Hao Xue, Zhi-Jun Chen, Hong-Hua Zhang iD, Xiang-Ping Zhu, Keng-Long Huang, Cai-Ni Yang iD, Ke Zhu, Hao-Ming Lin, Rui Zhang

MedComm · 2025-12 · 6 (12)

DOI: 10.1002/mco2.70504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 26.11.2025. Verfasst von Shu-Sheng Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are widely used for treating hepatocellular carcinoma (HCC), yet their efficacy remains limited, with suboptimal response rates. The predictive power of the current biomarker, programmed death ligand‐1 (PD‐L1), is limited by detection variability and glycosylation, underscoring the need for complementary biomarkers to enhance predictive accuracy. In this study, mass spectrometry was employed to identify proteomic alterations in HCC tissues from responders and nonresponders to anti‐programmed cell death‐1 (PD‐1) therapy. Survival analysis established the role of Yin Yang 1 (YY1) in determining ICI efficacy. Coculture models of hepatoma and CD8 + T cells revealed the immunosuppressive function of YY1. Transcriptome sequencing identified polypeptide N‐acetylgalactosaminyltransferase 16 (GALNT16) as a transcriptional target of YY1, and subsequent Western blot and coimmunoprecipitation assays demonstrated that GALNT16 augments PD‐L1 expression. Furthermore, in vivo mouse models demonstrated that YY1 knockdown potentiated the efficacy of anti‐PD‐1 therapy, an effect that was partially reversed by GALNT16 overexpression. Specifically, YY1 upregulates GALNT16, which in turn promotes PD‐L1 glycosylation and stability, leading to diminished CD8 + T cell activity. Thus, GALNT16 knockdown rescued the compromised CD8 + T cell cytotoxicity induced by YY1. Collectively, these results elucidate the YY1/GALNT16/PD‐L1 axis as a pivotal mechanism underlying HCC resistance to ICI therapy. This highlights the therapeutic potential of targeting PD‐L1 glycosylation pathways.

Schlagwörter

Stichwörter der Autor:innen

Yin Yang 1hepatocellular carcinomaimmune checkpoint inhibitorspolypeptide N‐acetylgalactosaminyltransferase 16programmed death ligand‐1 glycosylation

Autor:innen und Institutionen

  • Department of Biliary-Pancreatic Surgery Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
  • Guangzhou Key Laboratory of Precise Diagnosis and Treatment of Biliary Tract Cancer Sun Yat-sen Memorial Hospital Sun Yat-sen University Guangzhou China.
  • Department of Thoracic Surgery Guangzhou First People's Hospital Guangzhou Medical University Guangzhou China.
  • Center For Medical Research On Innovation and Translation Guangzhou First People's Hospital Guangzhou Medical University Guangzhou China.
  • Department of Hepatobiliary Surgery Southwest Hospital Third Military Medical University (Army Medical University) Chongqing China.
  • Department of Oncology Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.

ORCID-Profile: Gang Xiao, Hong-Hua Zhang, Cai-Ni Yang

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Provincial Department of Science and Technology

Zitieren

APA

Lin, S. S., Xiao, G., Liu, Q. Q., Xue, J. H., Chen, Z. J., Zhang, H. H., Zhu, X. P., Huang, K. L., Yang, C. N., Zhu, K., Lin, H. M., & Zhang, R. (2025). Yin Yang 1 Promotes Antiprogrammed Cell Death‐1 Resistance in Hepatocellular Carcinoma through Polypeptide N‐Acetylgalactosaminyltransferase 16‐Mediated Glycosylation of Programmed Death Ligand‐1. MedComm, 6(12). https://doi.org/10.1002/mco2.70504

Vancouver

Lin SS, Xiao G, Liu QQ, Xue JH, Chen ZJ, Zhang HH, et al. Yin Yang 1 Promotes Antiprogrammed Cell Death‐1 Resistance in Hepatocellular Carcinoma through Polypeptide N‐Acetylgalactosaminyltransferase 16‐Mediated Glycosylation of Programmed Death Ligand‐1. MedComm. 2025;6(12). doi:10.1002/mco2.70504

BibTeX
@article{Lin2025,
  author = {Lin, Shu-Sheng and Xiao, Gang and Liu, Qin-Qin and Xue, Jia-Hao and Chen, Zhi-Jun and Zhang, Hong-Hua and Zhu, Xiang-Ping and Huang, Keng-Long and Yang, Cai-Ni and Zhu, Ke and Lin, Hao-Ming and Zhang, Rui},
  title = {Yin Yang 1 Promotes Antiprogrammed Cell Death‐1 Resistance in Hepatocellular Carcinoma through Polypeptide N‐Acetylgalactosaminyltransferase 16‐Mediated Glycosylation of Programmed Death Ligand‐1},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {12},
  doi = {10.1002/mco2.70504}
}
Kostenlos starten →